Heterologous versus homologous boosting regimens elicit qualitatively distinct, BA.5 cross reactive T cells in transplant recipients
Elizabeth A. Thompson(North Carolina State University), Andrea L. Cox(Johns Hopkins University), Joel N. Blankson(Johns Hopkins University), Dorry L. Segev(New York University), Laila Stoddart, William A. Werbel(Johns Hopkins University), Wabathi Ngecu, Aaron A.R. Tobian(Johns Hopkins University), Andrew H. Karaba(Johns Hopkins University), Jennifer L. Alejo(Johns Hopkins University), Amy Chang(Johns Hopkins University), Katherine Cascino(Johns Hopkins University), T. Scott Johnson(Johns Hopkins University), Aura T. Abedon(Johns Hopkins University)
Cited by 0
Related Papers
Foot strike patterns and collision forces in habitually barefoot versus shod runners
|Nature|2010|1.4k
Clinical Practice Guidelines From the AABB
|JAMA|2016|1.1k
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
|American Journal of Transplantation|2017|1k
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
|JAMA|2021|1k
Deployment of convalescent plasma for the prevention and treatment of COVID-19
|Journal of Clinical Investigation|2020|863